Guardant Health has released a blood test for use in the U.S. to identify early colorectal cancer in average-risk adults. The company said that research supports the efficacy of its Shield test for early colon cancer detection.
In a validation effort using 309 patient samples (including 92 with colorectal cancer), the Shield test showed a sensitivity of 91% and a specificity of 92% for detecting colorectal cancer. It is intended for adults 45 years and older who are not current with screening recommendations, are asymptomatic, and are at average risk for the disease.
